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Abstract 
Neurogranin (Ng) is a novel marker proposed to measure neurodegeneration in Alzheimer’s 
disease and to be associated with synaptic plasticity. It was tested whether a course of 
electroconvulsive therapy (ECT) could modify CSF Ng concentration. CSF Ng concentrations 
were measured before and after a course of ECT in the cerebrospinal fluid in twelve patients 
with major depression. Ng concentrations did not change during ECT, but baseline levels were 
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Introduction 
Electroconvulsive therapy (ECT) is a highly effective, non-pharmacological treatment option 
for severe and treatment-resistant forms of depression, mania and schizophrenia. The 
complex mode of action of ECT has not yet been fully unravelled, but among other mechanism, 
it is considered to facilitate neurogenesis and neural plasticity (Inta et al. 2013; Rotheneichner 
et al. 2014; Sartorius et al. 2009). Recently, the interplay between antidepressant treatment 
and amyloid  (Aβ) metabolism in humans was investigated by analyzing the antidepressant 
effects of ECT on Aβ peptides in the cerebrospinal fluid (CSF) in patients with major 
depression. CSF levels of Aβ 1-42, one of the major key players in the pathogenesis of 
Alzheimer’s disease (AD), were elevated after the ECT treatment and an increase of Aβ1-42 
after ECT was found in all patients with clinical response to the ECT treatment, but not in those 
who did not respond (Kranaster et al. 2016). In contrast to this, Aβ1-40 and tau protein and its 
abnormal phosphorylated isoform were not altered by ECT. 
To complement the evaluation of the effect of ECT on proteins involved in neurodegeneration, 
neurogranin (Ng), a novel marker, that has been suggested to measure neurodegeneration in 
AD and is highly correlated with tau and Aβ pathology in AD (Mattsson et al. 2016) was 
analysed. Ng is a post-synaptic protein (Gerendasy and Sutcliffe 1997) and its CSF level is a 
putative marker of synaptic loss in AD and it is associated with brain atrophy (Portelius et al. 
2015). Ng is expressed in the cortex and hippocampus by excitatory neurons (Represa et al. 
1990; Guadano-Ferraz et al. 2005), has a key role in synaptic plasticity and induction of long-
term potentiation (LTP) in the hippocampus (Fedorov et al. 1995; Chen et al. 1997) and could 
restore Aβ-mediated synaptic plasticity deficits (Kaleka and Gerges 2016).  
Based on these findings, we aimed to test, whether the neuronal plasticity, which is known to 
be enhanced by ECT (Joshi et al. 2016) is mediated by Ng modulation that could be detected 
by changes of Ng levels in the CSF in patients who receive ECT due to their major depression. 
  




Our prospective study was approved by the ethics committee and was performed in 
accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki). 
Written informed consent was obtained from all participants prior to enrolment. The study took 
place from 2013 to 2015 at the Department of Psychiatry at the Central Institute of Mental 
Health in Mannheim, Germany. Inclusion criteria were a present depressive episode within the 
context of a diagnosis of either major depressive disorder or bipolar disorder according to 
DSM-IV, age above 18 years and the clinical decision for an ECT treatment. Exclusion criteria 
were substance-related disorders and a lifetime diagnosis of schizophrenia. The Hamilton 
Depression Rating Scale (HDRS; 21 items version) and Mini-Mental-State Examination 
(MMSE) were used to assess the severity of depression and cognitive performance, 
respectively, before and after the ECT in each patient.  
ECT treatment 
ECT was performed with a Thymatron IV device (Somatics, LLC. Lake Bluff, IL, USA) with 900 
mA constant current and bidirectional brief pulse stimulation. S-ketamine was used as the 
anaesthetic substance (~1.0 mg/kg) (Hoyer et al. 2014; Kranaster et al. 2011) and 
succinylcholine was used for muscle relaxation (~1.0 mg/kg). Seizure threshold in all patients 
was titrated and stimulus dose at subsequent treatments was given at 2.5 times threshold. The 
charge was subsequently increased if patients did not respond clinically or if seizures were 
insufficient during the ECT course according to established recommendations (American 
Psychiatric Association 2001). Two or three ECT sessions per week were performed. All 
patients started with right unilateral stimulation, in the case of non-response it was possible to 
switch to bilateral stimulation as a decision of the ECT supervisor.   
Sampling 
Before the first ECT session and between one and seven days after the last ECT session, CSF 
samples were drawn at around 9:00 am. The patients were in a non-fasting status. They had 
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a light breakfast at 8:00 am. Lumbar punctures were performed in the sitting position according 
to standardized procedure. CSF samples (X mL) were obtained, centrifuged (2000 x g?), 
aliquoted into XXX mL portions that were frozen at -80°C within 30 min. The samples were 
stored at -80°C and were never thawed or refrozen prior to Ng analysis.  
CSF laboratory analyses 
All samples were measured at the Clinical Neurochemistry Laboratory at Sahlgrenska 
University Hospital. CSF Ng concentration was measured by enzyme-linked immunosorbent 
assay (ELISA), essentially as described (http://www.ncbi.nlm.nih.gov/pubmed/25533203), 
using the anti-Ng antibody pair Ng2 and Ng22. Baseline and follow-up samples were analyzed 
on one occasion on the same plates using the same batch of reagents. Intra-assay coefficients 
of variation were below 10%.  
Statistical analyses 
Statistics were performed using STATA® (StataCorp, Texas 77845, USA, version 11) at a 
significance level ≤0.05. Non-parametric tests were used, because the Ng levels were not 
normally distributed. The impact of ECT on changes in the CSF Ng concentration was 
calculated with the Wilcoxon matched-pairs signed-ranks test. Correlations were tested with 
the Spearman’s rank correlation. In the case of values below the level of detection (LOD), it 
was decided to substitute them with LOD/2, although we are aware of the potential bias and 
imprecision (Ogden 2010). 
Results 
We included twelve patients into the study, who underwent a completed course of ECT and 
lumbar puncture prior to and following a treatment course. In five samples, neurogranin levels 
were below the limit of detection of 40 pg/ml (in two patients in both samples and in another 
patient in the baseline sample). Demographic and clinical features are shown in Table 1.  
Differences before and after ECT 
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CSF neurogranin concentration at baseline (117.7 pg/ml ±107.0) and after the complete ECT 
treatment (122.8 pg/ml ±80.4) did not differ from each other (p=0.15). The mean neurogranin 
baseline level in the group of those patients suffering from Alzheimer’s disease (AD) was 
higher (179.5 pg/ml ±77.8) at a trend level significance than the mean level of the patients, 
who did not suffer from AD (97.1 pg/ml ±111.0; p=0.077). The change in neurogranin levels 
during ECT did not differ in these two groups (p=0.78).  
Correlation with numbers of ECT sessions 
The changes from baseline to final levels were not associated with the number of single ECT 
sessions that were performed in each patient (p=0.74). 
Antidepressant efficacy 
The changes of neurogranin levels during ECT were neither associated with change of 
depressive psychopathology during ECT (p=0.93), nor with therapeutic response (p=0.26) or 
remission (p=0.94). The baseline level of CSF neurogranin was positively correlated with the 
reduction of depressive psychopathology during ECT (Figure 1; rs=0.64; p=0.024) and the 
therapeutic response (rs=0.59; p=0.045). 
Possible moderators 
In our sample, CSF neurogranin levels were not associated with age (p=0.37), sex (p=0.94), 
bipolarity (p=0.93), education (p=0.51) and MMSE at baseline (p=0.90).  
Discussion 
This is the first study to investigate changes of Ng CSF levels in response to ECT treatment in 
patients suffering from depression. In contrast to the reported changes in the Aβ metabolism 
during ECT (Kranaster et al. 2016), we could not detect an alteration of the synaptic protein 
Ng during ECT and no associated with the changes of CSF Ng levels and the number of 
individual ECT sessions. Thus, CSF Ng concentration does not seem to reflect the enhanced 
neuronal plasticity that has been observed after ECT (Joshi et al. 2016). 
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As a secondary finding, the baseline level of CSF Ng was positively correlated with the 
reduction of depressive psychopathology and a better therapeutic response to ECT. Because 
the role of Ng in mood disorders has not been investigated in-depth yet, our data are the first 
concerning prediction of antidepressant treatment response based on CSF Ng levels. There 
is only one previous report, in which data on CSF Ng levels in patients with major depressive 
disorder were reported. Their cohort consisted only of six patients, but interestingly all of them 
had considerable low CSF Ng levels (Sanfilippo et al. 2016). Although measured by the same 
group, the research grade assay was modified in-between, which makes it impossible to set 
our data in perspective with the historical data to test whether the Ng concentration in our 
sample of depressive patients are also lower compared to age-matched healthy controls or to 
patients with neurodegenerative diseases. One very indirect hint, that the CSF Ng 
concentration in our patients can also be considered as considerable low is that in three out of 
twelve patients (25%) at baseline the Ng levels were under the limit of detection. At least, no 
similar pattern was reported in previous cohorts of healthy controls (Sanfilippo et al. 2016; 
Portelius et al. 2015). Additionally, Ng has been recognized as a susceptibility gene of 
major depression and bipolar disorder (and schizophrenia) in Han Chinese (Wen et al. 2016). 
Based on these few data, it could be speculated, that Ng has indeed a role in the development 
and treatment of major depression and that it might be worthwhile to evaluate the potential 
interplay of Ng and depression in more detail. 
The major limitation of this study is the small sample size, but the difficulty in recruiting severely 
depressed patients who agree to undergo lumbar puncture twice for research purposes only 
in addition to a course of ECT should not be underestimated. It could not be excluded, that the 
insufficient power lead to the negative primary finding. However, it was possible to detect 
changes in other systems with that small sample size (Kranaster et al. 2017b; Kranaster et al. 
2017a) and at least a strong effect of ECT on Ng appears unlikely.  
In conclusion, mean CSF Ng concentrations did not change during a course of ECT, but the 
apparently low baseline Ng levels in the patients with major depression were positively 
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correlated the amount of therapeutic response, which suggests an involvement of Ng in 
depression. 
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Tables 
Number of included subjects 12 
Age (mean) ± SE in years (min - max) 59.0 ± 21.9 (21 - 83) 
Sex female/male n/n (in %) 7/5 (58.3/41.7) 
Type of depression: unipolar/bipolar n/n (in %) 9/3 (75.0/25.0) 
HDRS, sum score  
   Baseline HDRS, mean ± SE (min - max) 29.9 ± 6.6 (21 - 41) 
   Final HDRS, mean ± SE (min - max) 9.0 ± 5.2 (3 - 16) 
   Mean change (min - max) -20.9 (-6 - -36) (p<0.001) 
Numbers of ECT sessions, mean ± SE (min - max) 10.6 ±5.0 (4 - 19) 
Switch to bilateral stimulation n (in %) 3 (25) 
Responders/Non-responders* n/n (in %) 10/2 (83.4/16.7) 
MMSE, sum score  
   Baseline MMSE, mean ± SE (min - max) 26.1 ± 4.3 (17 - 30) 
   Final MMSE mean ± SE (min - max) 26.6 ± 3.7 (18 - 30) 
   Mean change (min - max) 0.6 (-2 - 4) (p=0.30) 
Table 1: Demographic and clinical features of the patients.  
* Response is defined as a reduction of at least 50% in symptoms, measured by the HDRS. 





Figure 1: Correlation between CSF Ng levels at baseline and the reduction of the HDRS 
during ECT (rs=0.64; p=0.024). 
 
